← Leaderboards
Michael Leo Fitzgerald
Massachusetts General Hospital
$6,905,590
Attributed
$14,554,018
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$14,554,018 · 6
By mechanism
R01$14,460,274 · 5
F32$93,744 · 1
Top collaborators
- Michael Ilya Bukrinsky12 shared
- Eicke Latz9 shared
- Dmitri Sviridov8 shared
- Janet Lo4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Janet Lo$8,224,042
- Mason W Freeman$16,094,693
- Ahmed A Tawakol$9,912,063
- Filip K Swirski$20,484,870
- David E Fisher$28,420,496
Others in their field
Top investigators on “High Density Lipoproteins”
- Daniel James Rader · University Of Pennsylvania$45,161,673
- Eric A Boerwinkle · University Of Texas Hlth Sci Ctr Houston$32,518,468
- Richard T D'aquila · Massachusetts General Hospital$27,454,413
- Steven Kyle Grinspoon · Massachusetts General Hospital$24,968,109
- Alan Richard Tall · Columbia University Health Sciences$24,241,820
- Pamela Susan Douglas · Duke University$24,138,491
Research focus
High Density LipoproteinsMediatingAtherosclerosisImmuneCardiovascular DiseasesLipidsHiv InfectionsInfectionPlasmaProteinsCellsMacrophageProgramsPlayStructureResponseIn VitroCholesterolMouse ModelArterial Fatty StreakInflammatoryCardiovascular Disorder RiskLeadPrevention
Grant awards (27)
Epigenetic Reprogramming in HIV-Associated Cardio-Vascular Disease$777,389
R01 · FY2021 · HL
Epigenetic Reprogramming in HIV-Associated Cardio-Vascular Disease$784,578
R01 · FY2020 · HL
Epigenetic Reprogramming in Atherosclerosis$673,647
R01 · FY2020 · HL
Epigenetic Reprogramming in HIV-Associated Cardio-Vascular Disease$793,579
R01 · FY2019 · HL
Epigenetic Reprogramming in Atherosclerosis$673,647
R01 · FY2019 · HL
Epigenetic Reprogramming in HIV-Associated Cardio-Vascular Disease$787,681
R01 · FY2018 · HL
Epigenetic Reprogramming in Atherosclerosis$673,647
R01 · FY2018 · HL
Epigenetic Reprogramming in Atherosclerosis$690,522
R01 · FY2017 · HL
HDL prevention of cholesterol crystal inflammation in HIV disease$605,847
R01 · FY2016 · HL · contact PI
HIV Disease and Impairement of High Density Lipoprotein Metabolism$728,214
R01 · FY2015 · HL
HDL prevention of cholesterol crystal inflammation in HIV disease$602,921
R01 · FY2015 · HL · contact PI
HIV Disease and Impairement of High Density Lipoprotein Metabolism$727,875
R01 · FY2014 · HL
HDL prevention of cholesterol crystal inflammation in HIV disease$605,998
R01 · FY2014 · HL · contact PI
HIV Disease and Impairement of High Density Lipoprotein Metabolism$677,773
R01 · FY2013 · HL
HDL prevention of cholesterol crystal inflammation in HIV disease$593,424
R01 · FY2013 · HL · contact PI
HIV Disease and Impairement of High Density Lipoprotein Metabolism$716,126
R01 · FY2012 · HL
HDL prevention of cholesterol crystal inflammation in HIV disease$646,768
R01 · FY2012 · HL · contact PI
HIV Disease and Impairement of High Density Lipoprotein Metabolism$156,292
R01 · FY2012 · HL
HIV Disease and Impairement of High Density Lipoprotein Metabolism$124,801
R01 · FY2012 · HL
HIV Disease and Impairement of High Density Lipoprotein Metabolism$124,801
R01 · FY2011 · HL
HIV Disease and Impairement of High Density Lipoprotein Metabolism$748,717
R01 · FY2010 · HL
ABCA1 cholesterol efflux & protein-protein interactions$373,347
R01 · FY2008 · HL · contact PI
ABCA1 cholesterol efflux & protein-protein interactions$373,347
R01 · FY2007 · HL · contact PI
ABCA1 cholesterol efflux & protein-protein interactions$384,498
R01 · FY2006 · HL · contact PI
ABCA1 cholesterol efflux &protein-protein interactions$414,835
R01 · FY2005 · HL
FUNCTIONAL ANALYSIS OF THE TANGIER DISEASE GENE ABC1$49,412
F32 · FY2001 · HL
FUNCTIONAL ANALYSIS OF THE TANGIER DISEASE GENE ABC1$44,332
F32 · FY2000 · HL